Literature DB >> 11335754

Impact of the Joint Statement by the American Academy of Pediatrics/US Public Health Service on thimerosal in vaccines on hospital infant hepatitis B vaccination practices.

M B Hurie1, T N Saari, J P Davis.   

Abstract

OBJECTIVE: To determine the impact of the American Academy of Pediatrics/US Public Health Service (AAP/USPHS) joint statement on thimerosal in vaccines on hospital infant hepatitis B vaccination policies in Wisconsin.
METHODS: The nurse managers of hospital newborn nurseries (n = 110) were surveyed by mail. Nonresponders were resurveyed. Twelve hospitals no longer provided obstetric services. Of the remaining 98 hospitals, 84 (86%) responded to the initial mailing and 14 (14%) responded to the second mailing. The number of hospitals that offered hepatitis B vaccine to infants before July 1999 was compared with that in March 2000. The number of hospitals that had policies in place to vaccinate infants whose mothers' hepatitis B surface antigen status (HBsAg) was positive or unknown during the thimerosal alert (July 1999 through November 1999) was compared with that in March 2000.
RESULTS: Before July 1999, 81% of the hospitals representing 84% of reported Wisconsin births routinely offered hepatitis B vaccine to all infants. By March 2000, 50% of hospitals, representing 43% of births, had resumed routine infant hepatitis B vaccination. Physician decision to use a combination Haemophilus influenzae type b hepatitis B vaccine was the most frequently given reason for not reinstituting infant hepatitis B vaccination. During the thimerosal alert, 23% of hospitals did not have policies to vaccinate infants whose mothers were HBsAg-positive and 51% did not have policies to vaccinate infants whose mothers' HBsAg status was unknown. By March 2000, 6% of hospitals still did not have policies to vaccinate infants whose mothers were HBsAg-positive and 24% did not have policies to vaccinate infants whose mothers' HBsAg status was unknown.
CONCLUSION: The AAP/USPHS joint statement on thimerosal in vaccines has resulted in a 38% decrease in the number of hospitals routinely offering infants hepatitis B vaccine. Although thimerosal-free hepatitis B vaccine is now available, some hospitals still do not have appropriate policies in place for vaccinating infants whose mothers' HBsAg status is positive or unknown. In the future, policymakers should include anticipated consequences that may result from changes in immunization policy in their recommendations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11335754     DOI: 10.1542/peds.107.4.755

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  5 in total

1.  A retrospective study of administration of vaccination for hepatitis B among newborn infants prior to hospital discharge at a midwestern tertiary care center.

Authors:  Helen I Myers; Cassandra N Spracklen; Kelli K Ryckman; Jeffrey C Murray
Journal:  Vaccine       Date:  2015-03-31       Impact factor: 3.641

Review 2.  Issues in the formulation of drugs for oral use in children: role of excipients.

Authors:  Shiwaji Pawar; Ashir Kumar
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

3.  Impact of the introduction of pneumococcal conjugate vaccine on immunization coverage among infants.

Authors:  Nancy D Lin; Ken Kleinman; K Arnold Chan; Xian-Jie Yu; Eric K France; Stanley Xu; Feifei Wei; John Mullooly; Jeanne Santoli; Tracy A Lieu
Journal:  BMC Pediatr       Date:  2005-11-28       Impact factor: 2.125

4.  Variation in hepatitis B immunization coverage rates associated with provider practices after the temporary suspension of the birth dose.

Authors:  Nancy D Lin; Ken Kleinman; K Arnold Chan; Xian-Jie Yu; Eric K France; Feifei Wei; John P Mullooly; Steven Black; David K Shay; Margarette Kolczak; Tracy A Lieu
Journal:  BMC Pediatr       Date:  2006-11-13       Impact factor: 2.125

Review 5.  The Vaccine-Hesitant Moment.

Authors:  Heidi J Larson; Emmanuela Gakidou; Christopher J L Murray
Journal:  N Engl J Med       Date:  2022-06-29       Impact factor: 176.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.